RecruitingPhase 4NCT06824103
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
Studying Graft versus host disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Ruxolitinib(drug)
- Enrollment
- 50 target
- Eligibility
- 12-100 years · All sexes
- Timeline
- 2025 – 2032
Study locations (17)
- Novartis Investigative Site, Hefei, Anhui, China
- Novartis Investigative Site, Guangzhou, Guangdong, China
- Novartis Investigative Site, Nanning, Guangxi, China
- Novartis Investigative Site, Guiyang, Guizhou, China
- Novartis Investigative Site, Shijiazhuang, Hebei, China
- Novartis Investigative Site, Zhengzhou, Henan, China
- Novartis Investigative Site, Wuhan, Hubei, China
- Novartis Investigative Site, Nanjing, Jiangsu, China
- Novartis Investigative Site, Nanchang, Jiangxi, China
- Novartis Investigative Site, Chengdu, Sichuan, China
- Novartis Investigative Site, Hangzhou, Zhejiang, China
- Novartis Investigative Site, Ningbo, Zhejiang, China
- Novartis Investigative Site, Wenzhou, Zhejiang, China
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Changsha, China
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06824103 on ClinicalTrials.govOther trials for Graft versus host disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07166848Electrostimulation Study for Ocular Graft vs. Host DiseaseZhonghui K. Luo, MD, PhD
- RECRUITINGPHASE2NCT07246031BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell TransplantationBioPhoenix Co., Ltd.
- RECRUITINGNANCT07184853Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHDFirst Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE2NCT07118254A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)Lubris Bio Pty Ltd
- RECRUITINGPHASE3NCT07047456Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBTAnhui Provincial Hospital
- RECRUITINGPHASE2NCT06799195Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell TransplantationUniversity of Nebraska
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07162688Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.Fujian Medical University
- RECRUITINGNCT07314892Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD).Medical University of Gdansk